Literature DB >> 7087801

Antimicrobial susceptibility of Clostridium difficile from different sources.

S Nakamura, S Nakashio, M Mikawa, K Yamakawa, S Okumura, S Nishida.   

Abstract

A total of 79 Clostridium difficile strains from healthy young and elderly adults, elderly patients without gastrointestinal disease, elderly patients receiving antibiotics without gastrointestinal complications, and elderly patients with antibiotic-associated diarrhea or pseudomembranous colitis were tested for their susceptibilities to 24 antimicrobial agents. All of the 79 strains were inhibited by low concentrations of rifampicin, metronidazole, fusidic acid, vancomycin, ampicillin, and penicillin G. Strains were highly resistant to aminoglycosides, trimethoprim, sulfamethoxazole, nalidixic acid, and cycloserine and often resistant to neomycin, cefoxitin, and cefalexin. Wide variations in the susceptibility of C. difficile strains to erythromycin, clindamycin, lincomycin, chloramphenicol, and tetracycline were found. Strains resistant to erythromycin, clindamycin, and lincomycin were more frequently found among strains isolated from elderly adults than those isolated from young adults, with particularly high frequency among strains isolated from elderly patients receiving antibiotics. None of the 23 strains isolated from healthy young adults was resistant to chloramphenicol. All of the 14 strains resistant to erythromycin, clindamycin, lincomycin, and chloramphenicol were sensitive to tetracycline and all of the 15 strains resistant to erythromycin, clindamycin, lincomycin, and tetracycline were sensitive to chloramphenicol. Only one out of 19 tetracycline, resistant strains was highly toxigenic, whereas 42 (70%) of the 60 sensitive strains were highly toxigenic.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7087801     DOI: 10.1111/j.1348-0421.1982.tb00150.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  8 in total

1.  Comparative analysis of the extracellular proteomes of two Clostridium sordellii strains exhibiting contrasting virulence.

Authors:  Maureen T Kachman; Mary C Hurley; Teri Thiele; Geetha Srinivas; David M Aronoff
Journal:  Anaerobe       Date:  2010-03-23       Impact factor: 3.331

2.  Correlation between susceptibility to chloramphenicol, tetracycline and clindamycin, and serogroups of Clostridium difficile.

Authors:  S Nakamura; K Yamakawa; S Nakashio; S Kamiya; S Nishida
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  Transferable resistance to clindamycin, erythromycin, and tetracycline in Clostridium difficile.

Authors:  J Wüst; U Hardegger
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

4.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Laboratory diagnosis of Clostridium difficile-associated diarrhoea.

Authors:  R A Bowman; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

6.  Effect of L-cysteine on the activity of penicillin antibiotics against Clostridium difficile.

Authors:  S M Markowitz; D S Williams
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.

Authors:  Andrea C Büchler; Silvana K Rampini; Simon Stelling; Bruno Ledergerber; Silke Peter; Alexander Schweiger; Christian Ruef; Reinhard Zbinden; Roberto F Speck
Journal:  BMC Infect Dis       Date:  2014-11-26       Impact factor: 3.090

Review 8.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.